Literature DB >> 31659318

Structure of an allosteric modulator bound to the CB1 cannabinoid receptor.

Zhenhua Shao1, Wei Yan1, Karen Chapman2, Karthik Ramesh2, Aaron J Ferrell2, Jie Yin2, Xuehui Wang1, Qingping Xu3, Daniel M Rosenbaum4.   

Abstract

The CB1 receptor mediates the central nervous system response to cannabinoids, and is a drug target for pain, anxiety and seizures. CB1 also responds to allosteric modulators, which influence cannabinoid binding and efficacy. To understand the mechanism of these compounds, we solved the crystal structure of CB1 with the negative allosteric modulator (NAM) ORG27569 and the agonist CP55940. The structure reveals that the NAM binds to an extrahelical site within the inner leaflet of the membrane, which overlaps with a conserved site of cholesterol interaction in many G protein-coupled receptors (GPCRs). The ternary structure with ORG27569 and CP55940 captures an intermediate state of the receptor, in which aromatic residues at the base of the agonist-binding pocket adopt an inactive conformation despite the large contraction of the orthosteric pocket. The structure illustrates a potential strategy for drug modulation of CB1 and other class A GPCRs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31659318     DOI: 10.1038/s41589-019-0387-2

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  49 in total

1.  Allosteric modulation of the cannabinoid CB1 receptor.

Authors:  Martin R Price; Gemma L Baillie; Adèle Thomas; Lesley A Stevenson; Morag Easson; Richard Goodwin; Adèle McLean; Lorraine McIntosh; Gillian Goodwin; Glenn Walker; Paul Westwood; Julia Marrs; Fiona Thomson; Phillip Cowley; Arthur Christopoulos; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2005-08-19       Impact factor: 4.436

2.  Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.

Authors:  Jonathan F Fay; David L Farrens
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

Review 3.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

Review 4.  Structural insights into G-protein-coupled receptor allostery.

Authors:  David M Thal; Alisa Glukhova; Patrick M Sexton; Arthur Christopoulos
Journal:  Nature       Date:  2018-07-04       Impact factor: 49.962

5.  CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.

Authors:  Gemma L Baillie; James G Horswill; Sharon Anavi-Goffer; Patricia H Reggio; Daniele Bolognini; Mary E Abood; Sean McAllister; Phillip G Strange; Gary J Stephens; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2012-11-15       Impact factor: 4.436

6.  A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569.

Authors:  Jonathan F Fay; David L Farrens
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

Review 7.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

8.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Authors:  Orrin Devinsky; J Helen Cross; Linda Laux; Eric Marsh; Ian Miller; Rima Nabbout; Ingrid E Scheffer; Elizabeth A Thiele; Stephen Wright
Journal:  N Engl J Med       Date:  2017-05-25       Impact factor: 91.245

Review 9.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

Authors:  Penny F Whiting; Robert F Wolff; Sohan Deshpande; Marcello Di Nisio; Steven Duffy; Adrian V Hernandez; J Christiaan Keurentjes; Shona Lang; Kate Misso; Steve Ryder; Simone Schmidlkofer; Marie Westwood; Jos Kleijnen
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

Review 10.  Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?

Authors:  George Kunos; Douglas Osei-Hyiaman; Sándor Bátkai; Keith A Sharkey; Alexandros Makriyannis
Journal:  Trends Pharmacol Sci       Date:  2008-11-29       Impact factor: 14.819

View more
  37 in total

Review 1.  Ligand binding at the protein-lipid interface: strategic considerations for drug design.

Authors:  Jian Payandeh; Matthew Volgraf
Journal:  Nat Rev Drug Discov       Date:  2021-07-13       Impact factor: 84.694

2.  Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia.

Authors:  Christopher J Draper-Joyce; Rebecca Bhola; Jinan Wang; Apurba Bhattarai; Anh T N Nguyen; India Cowie-Kent; Kelly O'Sullivan; Ling Yeong Chia; Hariprasad Venugopal; Celine Valant; David M Thal; Denise Wootten; Nicolas Panel; Jens Carlsson; Macdonald J Christie; Paul J White; Peter Scammells; Lauren T May; Patrick M Sexton; Radostin Danev; Yinglong Miao; Alisa Glukhova; Wendy L Imlach; Arthur Christopoulos
Journal:  Nature       Date:  2021-09-08       Impact factor: 49.962

3.  Identification of CB1 Ligands among Drugs, Phytochemicals and Natural-Like Compounds: Virtual Screening and In Vitro Verification.

Authors:  Adam Stasiulewicz; Anna Lesniak; Piotr Setny; Magdalena Bujalska-Zadrożny; Joanna I Sulkowska
Journal:  ACS Chem Neurosci       Date:  2022-10-05       Impact factor: 5.780

4.  Δ9 -Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors.

Authors:  Belén Palomares; Martín Garrido-Rodriguez; Claudia Gonzalo-Consuegra; María Gómez-Cañas; Suwipa Saen-Oon; Robert Soliva; Juan A Collado; Javier Fernández-Ruiz; Gaetano Morello; Marco A Calzado; Giovanni Appendino; Eduardo Muñoz
Journal:  Br J Pharmacol       Date:  2020-07-08       Impact factor: 8.739

5.  Structural determinants of cholesterol recognition in helical integral membrane proteins.

Authors:  Brennica Marlow; Georg Kuenze; Bian Li; Charles R Sanders; Jens Meiler
Journal:  Biophys J       Date:  2021-02-26       Impact factor: 4.033

6.  Current Trends in GPCR Allostery.

Authors:  Khuraijam Dhanachandra Singh; Sadashiva S Karnik
Journal:  J Membr Biol       Date:  2021-01-20       Impact factor: 1.843

Review 7.  Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.

Authors:  Lu Hou; Jian Rong; Ahmed Haider; Daisuke Ogasawara; Cassis Varlow; Michael A Schafroth; Linjing Mu; Jiefeng Gan; Hao Xu; Christopher J Fowler; Ming-Rong Zhang; Neil Vasdev; Simon Ametamey; Benjamin F Cravatt; Lu Wang; Steven H Liang
Journal:  J Med Chem       Date:  2020-12-30       Impact factor: 7.446

8.  In Vitro and In Silico Characterization of G-Protein Coupled Receptor (GPCR) Targets of Phlorofucofuroeckol-A and Dieckol.

Authors:  Pradeep Paudel; Su Hui Seong; Se Eun Park; Jong Hoon Ryu; Hyun Ah Jung; Jae Sue Choi
Journal:  Mar Drugs       Date:  2021-06-04       Impact factor: 5.118

9.  Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.

Authors:  Thuy Nguyen; Thomas F Gamage; Ann M Decker; David B Finlay; Tiffany L Langston; Daniel Barrus; Michelle Glass; Danni L Harris; Yanan Zhang
Journal:  Bioorg Med Chem       Date:  2021-05-12       Impact factor: 3.461

10.  Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting β2-Adrenergic Receptor Agonists.

Authors:  Christopher T Szlenk; Jeevan B Gc; Senthil Natesan
Journal:  Mol Pharmacol       Date:  2021-08-01       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.